Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11909)	12/1/1997 1:19:00 AM
From: CYBERKEN	Respond to of 32384

<<Ken, we both know that's just not true. You can predict that far ahead. Remember about 9 months ago you were predicting that ISIP would reach 100 within a year?>> Yeah? So a year ain't over yet!(:->) Actually, I'm out of Isis right now because I think there's a good move by Ligand into the "profitable biotech" catagory. The discussion as to when and how much on profitability for Ligand should begin in earnest when they choose the Lilly drug. Ligand (or is it Robinson?) has this tendency to make deals and plans that are very arcane and take even the most ardent fan of the company a while to figure out (excepting Henry, of course. He gets the idea on the first reading). As a result, the Lilly choice may surprise and initially disappoint many people. Then they will gradually change their minds as they study it. While this complexity thing is one of the features that keeps me glued to Ligand, I realize (especially after the Lilly deal) that it has short term negative effects on the stock. I get the Isis back whenever some of the "trading" warrants reach a compelling price. I really don't recommend any biotech investor be completely out of Isis for very long. I think the VD model would have stayed in except for that margin pressure. Some day, just for fun, I'm gonna find out if I can push my broker that far. (:->)